文献速递胸部肿瘤头颈与中枢神经肿瘤

奥希替尼治疗EGFR突变阳性非小细胞肺癌软脑膜转移:BLOOM研究

Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study.
PubMed 文献 · J Clin Oncol · 2019-12-06

BLOOM研究为I期研究,评估奥希替尼160mg每日一次在EGFR突变晚期非小细胞肺癌软脑膜转移患者中的疗效与安全性。41例患者入组,LM ORR(BICR)62%,DoR 15.2个月,中位PFS 8.6个月,中位OS 11.0个月,脑脊液肿瘤细胞清除率28%,安全性可控。

要点

  • 奥希替尼160mg每日一次在EGFRm NSCLC软脑膜转移中显示中枢神经系统疗效。
  • LM ORR(BICR)62%,DoR 15.2个月;研究者评估ORR 41%,DoR 8.3个月。
  • 中位PFS 8.6个月,中位OS 11.0个月,安全性及药代动力学与既往一致。

核心结论

  • 奥希替尼160mg每日一次在EGFRm NSCLC软脑膜转移患者中显示有意义的 CNS 疗效且安全性可控。

研究设计与样本

  • I期研究(BLOOM),纳入细胞学确诊软脑膜转移且既往EGFR-TKI治疗进展的EGFRm晚期NSCLC患者,共41例。

主要发现

  • LM ORR(BICR)为62%(95%CI 45%–78%),LM DoR(BICR)为15.2个月(95%CI 7.5–17.5个月)。
  • 研究者评估ORR为41%(95%CI 26%–58%),中位DoR为8.3个月(95%CI 5.6–16.5个月)。
  • 研究者评估中位PFS为8.6个月(95%CI 5.4–13.7个月,成熟度78%),中位OS为11.0个月(95%CI 8.0–18.0个月,成熟度68%)。
  • 40例中11例(28%,95%CI 15%–44%)确认脑脊液肿瘤细胞清除。
  • 基线神经功能异常21例中12例(57%)神经功能改善。

关键数值与推荐

  • 奥希替尼剂量为160mg每日一次。
  • LM疗效评估采用神经影像BICR(RANO-LM放射学标准)及研究者评估,可测量病灶按RECIST 1.1评估。

临床怎么用

  • 对于EGFRm晚期NSCLC伴软脑膜转移且既往EGFR-TKI治疗进展的患者,奥希替尼160mg每日一次可作为治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In this phase I study (BLOOM), osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), was evaluated in patients with leptomeningeal metastases (LMs) from EGFR-mutated (EGFRm) advanced non-small-cell lung cancer (NSCLC) whose disease had progressed on previous EGFR-TKI therapy. PATIENTS AND METHODS: Patients with cytologically confirmed LM received osimertinib 160 mg once daily. Objectives were to assess confirmed objective response rate (ORR), duration of response (DoR), progression-free survival (PFS), overall survival (OS), pharmacokinetics (PK), and safety. Additional efficacy evaluations included changes from baseline in CSF cytology and neurologic examination. Measurable lesions were assessed by investigator according to RECIST version 1.1. LMs were assessed by neuroradiologic blinded central independent review (BICR) according to Response Assessment in Neuro-Oncology LM radiologic criteria and by investigator. RESULTS: Forty-one patients were enrolled. LM ORR and DoR by neuroradiologic BICR were 62% (95% CI, 45% to 78%) and 15.2 months (95% CI, 7.5 to 17.5 months), respectively. Overall, ORR by investigator was 41% (95% CI, 26% to 58%), and median DoR was 8.3 months (95% CI, 5.6 to 16.5 months). Median investigator-assessed PFS was 8.6 months (95% CI, 5.4 to 13.7 months) with 78% maturity; median OS was 11.0 months (95% CI, 8.0 to 18.0 months) with 68% maturity. CSF tumor cell clearance was confirmed in 11 (28%; 95% CI, 15% to 44%) of 40 patients. Neurologic function was improved in 12 (57%) of 21 patients with an abnormal assessment at baseline. The adverse event and PK profiles were consistent with previous reports for osimertinib. CONCLUSION: Osimertinib showed meaningful therapeutic efficacy in the CNS and a manageable safety profile at 160 mg once daily in patients with EGFRm NSCLC and LM.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Yang JCH, Kim SW, Kim DW, et al. Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study. J Clin Oncol. 2019. PMID: 31809241. doi:10.1200/JCO.19.00457

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。